$CLDX
Celldex Therapeutics, Inc.

2021 Form 10-K Financial Statement

#000110465922028070 Filed on February 28, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $4.651M $3.790M $7.418M
YoY Change -37.3% 325.84% 107.61%
Cost Of Revenue $100.0K $200.0K
YoY Change -50.0% 100.0%
Gross Profit $4.551M $7.218M
YoY Change -36.95% 107.83%
Gross Profit Margin 97.85% 97.3%
Selling, General & Admin $20.49M $3.620M $14.46M
YoY Change 41.69% 12.42% -6.29%
% of Gross Profit 450.19% 200.33%
Research & Development $53.31M $10.43M $42.53M
YoY Change 25.34% 0.87% -0.32%
% of Gross Profit 1171.41% 589.28%
Depreciation & Amortization $3.068M $760.0K $3.929M
YoY Change -21.91% -33.91% -19.12%
% of Gross Profit 67.41% 54.43%
Operating Expenses $53.31M $14.07M $42.53M
YoY Change 25.34% 1.37% -0.32%
Operating Profit -$71.24M -$63.35M
YoY Change 12.45% 15.12%
Interest Expense $505.0K $1.940M $2.410M
YoY Change -79.05% -23.62% -41.93%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$70.74M -$22.84M -$60.95M
YoY Change 16.06% 118.56% 19.79%
Income Tax -$227.0K $900.0K -$1.167M
% Of Pretax Income
Net Earnings -$70.51M -$21.90M -$59.78M
YoY Change 17.95% 109.57% 17.49%
Net Earnings / Revenue -1516.04% -577.84% -805.88%
Basic Earnings Per Share -$1.64 -$2.02
Diluted Earnings Per Share -$1.64 -$552.3K -$2.02
COMMON SHARES
Basic Shares Outstanding 42.87K 29.64K
Diluted Shares Outstanding 42.87K 29.64K

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $408.3M $194.4M $194.4M
YoY Change 110.01% 201.86% 201.86%
Cash & Equivalents $39.14M $43.84M $43.80M
Short-Term Investments $369.1M $150.6M $150.6M
Other Short-Term Assets $2.417M $1.600M $1.600M
YoY Change 51.06% 23.08% 23.08%
Inventory
Prepaid Expenses
Receivables $172.0K $1.800M $1.800M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $410.8M $197.8M $197.8M
YoY Change 107.7% 196.62% 196.55%
LONG-TERM ASSETS
Property, Plant & Equipment $6.521M $3.815M $7.300M
YoY Change -10.67% -49.13% -2.67%
Goodwill
YoY Change
Intangibles $30.69M
YoY Change
Long-Term Investments
YoY Change
Other Assets $104.0K $41.00K $0.00
YoY Change
Total Long-Term Assets $33.82M $38.00M $38.00M
YoY Change -11.01% -32.39% -32.38%
TOTAL ASSETS
Total Short-Term Assets $410.8M $197.8M $197.8M
Total Long-Term Assets $33.82M $38.00M $38.00M
Total Assets $444.7M $235.8M $235.8M
YoY Change 88.57% 91.89% 91.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.228M $1.048M $1.000M
YoY Change 22.8% -12.67% -16.67%
Accrued Expenses $13.75M $8.459M $9.800M
YoY Change 40.27% 0.7% 16.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.53M $14.21M $14.20M
YoY Change 16.39% 22.47% 22.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.650M $10.12M $10.40M
YoY Change -16.83% -18.38% -16.13%
Total Long-Term Liabilities $8.650M $10.12M $10.40M
YoY Change -16.83% -18.38% -16.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.53M $14.21M $14.20M
Total Long-Term Liabilities $8.650M $10.12M $10.40M
Total Liabilities $25.18M $26.48M $26.50M
YoY Change -4.99% -8.37% -8.3%
SHAREHOLDERS EQUITY
Retained Earnings -$1.073B
YoY Change
Common Stock $1.280B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $419.5M $209.4M $209.4M
YoY Change
Total Liabilities & Shareholders Equity $444.7M $235.8M $235.8M
YoY Change 88.57% 91.89% 91.86%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$70.51M -$21.90M -$59.78M
YoY Change 17.95% 109.57% 17.49%
Depreciation, Depletion And Amortization $3.068M $760.0K $3.929M
YoY Change -21.91% -33.91% -19.12%
Cash From Operating Activities -$60.90M -$5.210M -$40.40M
YoY Change 50.73% -52.64% -12.95%
INVESTING ACTIVITIES
Capital Expenditures $1.249M -$240.0K $1.552M
YoY Change -19.52% 140.0% 112.31%
Acquisitions
YoY Change
Other Investing Activities -$214.9M $31.10M -$96.67M
YoY Change 122.31% 833.93% -642.78%
Cash From Investing Activities -$216.2M $30.85M -$98.22M
YoY Change 120.08% 858.07% -675.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $269.9M $170.8M
YoY Change 58.02% 951.16%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 272.4M 50.00K 171.2M
YoY Change 59.07% -97.93% 953.24%
NET CHANGE
Cash From Operating Activities -60.90M -5.210M -40.40M
Cash From Investing Activities -216.2M 30.85M -98.22M
Cash From Financing Activities 272.4M 50.00K 171.2M
Net Change In Cash -4.693M 25.69M 32.60M
YoY Change -114.39% -579.29% -349.3%
FREE CASH FLOW
Cash From Operating Activities -$60.90M -$5.210M -$40.40M
Capital Expenditures $1.249M -$240.0K $1.552M
Free Cash Flow -$62.15M -$4.970M -$41.96M
YoY Change 48.13% -54.4% -11.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39603771
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46730198
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0000744218
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.64
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.02
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.51
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42870
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29640
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14507
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.067
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
000-15006
CY2021 dei Entity Registrant Name
EntityRegistrantName
CELLDEX THERAPEUTICS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3191702
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
Perryville III Building
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
53 Frontage Road
CY2021 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 220
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Hampton
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08827
CY2021 dei City Area Code
CityAreaCode
908
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Local Phone Number
LocalPhoneNumber
200-7500
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $.001
CY2021 dei Trading Symbol
TradingSymbol
CLDX
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
30690000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
104000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41000
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
false
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
1300000000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46735026
CY2021 dei Auditor Firm
AuditorFirmId
238
CY2021 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39143000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43836000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
369107000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
150586000
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
172000
CY2020Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1802000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2417000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1619000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
410839000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
197843000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3551000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3815000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2970000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3449000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
27190000
CY2021Q4 us-gaap Assets
Assets
444654000
CY2020Q4 us-gaap Assets
Assets
235838000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1228000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1048000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12000000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8459000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1746000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1327000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1554000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3372000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16528000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14206000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1296000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2154000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7354000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10121000
CY2021Q4 us-gaap Liabilities
Liabilities
25178000
CY2020Q4 us-gaap Liabilities
Liabilities
26481000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
729000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
297000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
297000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46730198
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39603771
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
47000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
40000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1561142000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1279824000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1894000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2589000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1143607000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1073096000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
419476000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
209357000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
444654000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
235838000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4651000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7418000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3573000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53311000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42534000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42672000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20488000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14456000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15426000
CY2021 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
3500000
CY2020 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
18000000
CY2019 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1800000
CY2021 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
1405000
CY2020 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
4218000
CY2019 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
1294000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
75894000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
70772000
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
58604000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-71243000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-63354000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-55031000
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
505000
CY2020 us-gaap Interest And Other Income
InterestAndOtherIncome
2407000
CY2019 us-gaap Interest And Other Income
InterestAndOtherIncome
4153000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-70738000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-60947000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3915000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50878000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-227000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1167000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70511000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-59780000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50878000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.64
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.02
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.51
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42870
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29640
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14507
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70511000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-59780000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50878000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-695000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-30000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
36000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71206000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59810000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50842000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
124060000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
9000
CY2019 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
16248000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4551000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
36000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50878000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
94026000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
434000
CY2020 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
29431000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
141361000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-30000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-59780000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
209357000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2479000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
269893000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8953000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-695000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70511000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
419476000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70511000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-59780000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50878000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3068000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3929000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4858000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3209000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1140000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1167000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
8953000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3915000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
4551000
CY2021 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-1574000
CY2020 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
787000
CY2019 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-6599000
CY2019 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-2274000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1871000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
334000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-362000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
5000
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
39000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3653000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1638000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-321000
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-4405000
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-816000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
24000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
55000
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-11000
CY2021 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
3500000
CY2020 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
18000000
CY2019 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1800000
CY2021 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
1405000
CY2020 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
4218000
CY2019 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
1294000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-227000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60909000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40404000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46415000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
174947000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
123600000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
113173000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
389881000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
220321000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
95382000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1249000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1552000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
731000
CY2021 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
27000
CY2020 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
55000
CY2019 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
20000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-216156000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-98218000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17080000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
269893000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
170792000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60900000
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
27200000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentration of Credit Risk and of Significant Customers and Suppliers</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, marketable securities and accounts receivable. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest-bearing accounts at major financial institutions in excess of insured limits. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a high credit quality. The Company has not historically experienced credit losses from its accounts receivable and therefore has not established an allowance for doubtful accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Revenue from Rockefeller University and Gilead Sciences represented 88% and 85% of total Company revenue for the year ended December 31, 2021 and 2020, respectively. Combined revenue from Rockefeller University and Duke University represented 74% of total Company revenue for the year ended December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company relies on contract manufacturing organizations (CMO) to manufacture drug substance and drug product as well as for future commercial supplies. The Company also relies on CMOs for supply of raw materials as well as filling, packaging, storing and shipping our drug products.</p>
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16248000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2479000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
434000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
9000
CY2020 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
2962000
CY2020 us-gaap Repayments Of Debt
RepaymentsOfDebt
2962000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
272372000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
171226000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16257000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4693000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
32604000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13078000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43836000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11232000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24310000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39143000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43836000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11232000
CY2021 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
289000
CY2020 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
221000
CY2019 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
25000
CY2021 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(1) Nature of Business and Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Celldex Therapeutics, Inc. (the “Company” or “Celldex”) is a biopharmaceutical company dedicated to developing therapeutic monoclonal and bispecific antibodies that address diseases for which available treatments are inadequate. The Company is primarily focusing its efforts and resources on the continued research and development of CDX-0159, CDX-1140 and CDX-527.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors of the Company approved a <span style="-sec-ix-hidden:Hidden_tm0S1LtYfUGf9OC3IKZUOA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> for fifteen reverse stock split of the Company’s outstanding common stock, which was effected on February 8, 2019. All share and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split, including reclassifying an amount equal to the reduction in par value to additional paid-in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2021, the Company had cash, cash equivalents and marketable securities of $408.3 million. The Company has had recurring losses and incurred a loss of $70.5 million for the year ended December 31, 2021. Net cash used in operations for the year ended December 31, 2021 was $60.9 million. The Company believes that the cash, cash equivalents and marketable securities at the filing date of this Form 10-K will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months from the date of issuance of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the next twelve months and beyond, the Company may take further steps to raise additional capital to meet its long-term liquidity needs including, but not limited to, one or more of the following: the licensing of drug candidates with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. Although the Company has been successful in raising capital in the past, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company’s negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financings may be dilutive to the Company’s stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company’s ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company’s economic potential from products under development. The Company’s ability to continue funding its planned operations into and beyond twelve months from the issuance date is also dependent on the timing and manner of payment of contingent milestones from the Kolltan acquisition, in the event that the Company achieves the drug candidate milestones related to those payments. The Company, at its option, may decide to pay those milestone payments in cash, shares of its common stock or a combination thereof. If the Company is unable to raise the funds necessary to meet its long-term liquidity needs, it may have to delay or discontinue the development of one or more programs, discontinue or delay ongoing or anticipated clinical trials, license out programs earlier than expected, raise funds at a significant discount or on other unfavorable terms, if at all, or sell all or a part of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The COVID-19 pandemic continues to have a major impact in the US and around the world. The availability of vaccines holds promise for the future, though new variants of the virus and potential waning immunity from vaccines may result in continued impact from this pandemic in the future, which could adversely impact our operations. To date, the Company has managed delays and disruptions without significant impact in planned and ongoing preclinical and clinical trials, manufacturing or shipping. Potential impacts to our business include delays in planned and ongoing preclinical and clinical trials including enrollment of patients, disruptions in time and resources provided by independent clinical investigators, contract research organizations, and other third-party service providers, temporary closures of our facilities, disruptions or restrictions on our employees’ ability to travel, and delays in manufacturing and/or shipments to and from third-party suppliers and contract manufacturers for APIs and drug product. Any prolonged negative impacts to our business could materially impact our operating results and could lead to impairments of our intangible in-process research and development (“IPR&amp;D”) assets with a carrying value of $27.2 million at December 31, 2021.</p>
CY2021Q4 us-gaap Investments And Cash
InvestmentsAndCash
408300000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70500000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and use assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2019Q1 us-gaap Impairment Of Investments
ImpairmentOfInvestments
1800000
CY2018Q4 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
1800000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
700000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
2600000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
2600000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4077667
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3042229
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1700312
CY2019 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2020 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2021 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2021 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
1400000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
369809000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
702000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
369107000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
150593000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
150586000
CY2021Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2021Q4 us-gaap Interest Receivable
InterestReceivable
1300000
CY2020Q4 us-gaap Interest Receivable
InterestReceivable
200000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
1200000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
1500000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1800000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
2400000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.104
CY2019Q1 cldx Area Of Land Lease To Extend
AreaOfLandLeaseToExtend
33400
CY2019Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1900000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
2300000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
2500000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24677000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25052000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21126000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21237000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3551000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3815000
CY2019Q1 cldx Area Of Land Lease To Eliminate
AreaOfLandLeaseToEliminate
16200
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1970000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1269000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
73000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3312000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
270000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3042000
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
27200000
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
30700000
CY2021Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3500000
CY2020Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3500000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7968000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6113000
CY2021Q4 cldx Accrued Research And Development Contract Costs Current
AccruedResearchAndDevelopmentContractCostsCurrent
2871000
CY2020Q4 cldx Accrued Research And Development Contract Costs Current
AccruedResearchAndDevelopmentContractCostsCurrent
1590000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
878000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
421000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
283000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
335000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12000000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8459000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1613000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1840000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
6862000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
8267000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
433000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3386000
CY2021Q4 us-gaap Other Liabilities
OtherLiabilities
8908000
CY2020Q4 us-gaap Other Liabilities
OtherLiabilities
13493000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1554000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3372000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7354000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10121000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000
CY2020 cldx Expiration Of Net Operating Losses And Research And Development Tax Credits
ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
20294000
CY2021 cldx Expiration Of Net Operating Losses And Research And Development Tax Credits
ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
14210000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8953000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3915000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4551000
CY2020Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
400000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3400000
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3400000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
100000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
200000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
100000
CY2021 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-18513000
CY2020 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-16615000
CY2019 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-13869000
CY2021 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-7082000
CY2020 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-5802000
CY2019 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-2170000
CY2019 cldx Expiration Of Net Operating Losses And Research And Development Tax Credits
ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
18966000
CY2021 cldx Income Tax Expense Benefit Before Change In Valuation Allowance
IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance
-11385000
CY2020 cldx Income Tax Expense Benefit Before Change In Valuation Allowance
IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance
-2123000
CY2019 cldx Income Tax Expense Benefit Before Change In Valuation Allowance
IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance
2927000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-11158000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-956000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2927000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-227000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1167000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
183711000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
174369000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
47927000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
44936000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
59753000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
63215000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
14719000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-70738000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-60947000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50878000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-14855000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-12799000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-10684000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2422000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1778000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1902000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-7082000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-5802000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2170000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-941000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-1152000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-1011000
CY2021 us-gaap Income Tax Reconciliation Tax Contingencies Other
IncomeTaxReconciliationTaxContingenciesOther
-295000
CY2020 us-gaap Income Tax Reconciliation Tax Contingencies Other
IncomeTaxReconciliationTaxContingenciesOther
-886000
CY2019 us-gaap Income Tax Reconciliation Tax Contingencies Other
IncomeTaxReconciliationTaxContingenciesOther
-272000
CY2021 cldx Income Tax Reconciliation Expiration Of Net Operating Losses And Research And Development Tax Credits
IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
14210000
CY2020 cldx Income Tax Reconciliation Expiration Of Net Operating Losses And Research And Development Tax Credits
IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
20294000
CY2019 cldx Income Tax Reconciliation Expiration Of Net Operating Losses And Research And Development Tax Credits
IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
18966000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
11158000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
956000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-2927000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-227000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1167000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
13196000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1287000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1303000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
370000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
325000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
307767000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
297344000
CY2021Q4 cldx Deferred Tax Assets In Process Research And Development Intangible Assets
DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets
-6840000
CY2020Q4 cldx Deferred Tax Assets In Process Research And Development Intangible Assets
DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets
-7802000
CY2021Q4 cldx Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
300927000
CY2020Q4 cldx Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
289542000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
302540000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
291382000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1613000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1840000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1600000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1800000
CY2021Q4 cldx Operating Loss Carryforwards Not Subject To Expiration
OperatingLossCarryforwardsNotSubjectToExpiration
293800000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2021 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.60
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
400000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000

Files In Submission

Name View Source Status
0001104659-22-028070-index-headers.html Edgar Link pending
0001104659-22-028070-index.html Edgar Link pending
0001104659-22-028070.txt Edgar Link pending
0001104659-22-028070-xbrl.zip Edgar Link pending
cldx-20211231.xsd Edgar Link pending
cldx-20211231x10k.htm Edgar Link pending
cldx-20211231x10k002.jpg Edgar Link pending
cldx-20211231x10k_htm.xml Edgar Link completed
cldx-20211231xex21d1.htm Edgar Link pending
cldx-20211231xex23d1.htm Edgar Link pending
cldx-20211231xex31d1.htm Edgar Link pending
cldx-20211231xex31d2.htm Edgar Link pending
cldx-20211231xex32.htm Edgar Link pending
cldx-20211231_cal.xml Edgar Link unprocessable
cldx-20211231_def.xml Edgar Link unprocessable
cldx-20211231_lab.xml Edgar Link unprocessable
cldx-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending